Ten lessons from EGFR

Respir Investig. 2014 May;52(3):151-2. doi: 10.1016/j.resinv.2014.04.001.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Afatinib
  • Antineoplastic Agents
  • Clinical Trials as Topic
  • ErbB Receptors* / antagonists & inhibitors
  • ErbB Receptors* / genetics
  • Erlotinib Hydrochloride
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy
  • Mutation
  • Precision Medicine
  • Protein Kinase Inhibitors* / adverse effects
  • Protein Kinase Inhibitors* / pharmacology
  • Protein Kinase Inhibitors* / therapeutic use
  • Quinazolines* / adverse effects
  • Quinazolines* / pharmacology
  • Quinazolines* / therapeutic use

Substances

  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • Afatinib
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Gefitinib